Literature DB >> 16288870

The effect of dantrolene sodium in Very Long Chain Acyl-CoA Dehydrogenase Deficiency.

N C Voermans1, P J Poels, L A Kluijtmans, B G van Engelen.   

Abstract

We present a patient, who experienced recurrent episodes of rhabdomyolysis. Her beneficial response to treatment with dantrolene sodium was previously reported. Adult onset Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) deficiency has been diagnosed only recently. In adults, VLCAD deficiency results in recurrent fasting-, exercise-, or infection-induced muscle stiffness, muscle pain and myoglobinuria caused by rhabdomyolysis. This case illustrates for the first time the beneficial effect of dantrolene in VLCAD deficiency. We discuss the therapeutic mechanism of dantrolene sodium and its possible role as additional treatment modality for patients with VLCAD deficiency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288870     DOI: 10.1016/j.nmd.2005.09.003

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

1.  Adult-onset very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD).

Authors:  F Fatehi; A A Okhovat; Y Nilipour; M Mroczek; V Straub; A Töpf; A Palibrk; S Peric; V Rakocevic Stojanovic; H Najmabadi; S Nafissi
Journal:  Eur J Neurol       Date:  2020-07-24       Impact factor: 6.089

2.  Combined HIIT and Resistance Training in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency: A Case Report.

Authors:  Alba M Herrera-Olivares; Jose A Fernández-Luque; Carmen Paradas; Alejandro Lucia; Alfredo Santalla
Journal:  Front Physiol       Date:  2019-05-28       Impact factor: 4.566

3.  Adult-onset Repeat Rhabdomyolysis with a Very Long-chain Acyl-CoA Dehydrogenase Deficiency Due to Compound Heterozygous ACADVL Mutations.

Authors:  Yasuhiro Fuseya; Takeyo Sakurai; Jun-Ichi Miyahara; Kei Sato; Seiji Kaji; Yoshihiko Saito; Makio Takahashi; Ichizo Nishino; Tokiko Fukuda; Hideo Sugie; Hirofumi Yamashita
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.